If Horizon wants to make any headway in its hostile pursuit of Depomed, it's going to have to call a pair of shareholder meetings. First, though, its target's shareholders have to provide consent for those meetings--something proxy advisory firm ISS recommends they do.
Smiths Medical has faced its fair share of buyout rumors, with lagging revenues for its infusion pump business leaving some wondering when the company would close up shop. But the Minnesota devicemaker is undergoing a transformation under the stewardship of new CEO Jeff McCaulley, shrugging off talk of M&A as it revives its flagging fortunes.
Medtronic will buy stent retriever cover maker Lazarus Effect for $100 million in cash. The medical device giant expects to use the startup's novel nitinol mesh cover product, the Lazarus Cover, in conjunction with its own Solitaire stent retriever platform. Earlier this month, Medtronic rolled out a more effective catheter delivery system for Solitaire.
Mylan and its hostile takeover target, Perrigo, have been trading lawsuits in the U.S., but now they've taken their legal battle across the ocean.
In the latest move by a biopharma into med tech, Teva Pharmaceutical will acquire respiratory disease compliance startup Gecko Health Innovations for an undisclosed sum. This gives Teva its own in-house medication compliance tracking capabilities--and takes one of a handful of high-profile startups in this area off the market.
With a combo of its lead cancer drugs already designated as a breakthrough worthy of VIP treatment at the FDA, Aduro Biotech has now added in-house checkpoint inhibitors to the mix. The Berkeley, CA-based biotech announced Thursday after the markets closed that it is acquiring the Dutch biotech BioNovion for $32 million evenly divided between cash and stock.
Venn Life Sciences is expanding its reach across Europe, buying a small Dutch contractor to bolster its offerings in regulatory affairs.
The acquisitive BioClinica has picked up another service provider, buying a company specializing in safety monitoring and regulatory affairs to build out its offerings in drug development.
Investors embraced the acquisition of the surgical robotics division of the Italian healthcare company SOFAR by minimally invasive surgical robot company TransEnterix. The deal is for up to $99.8 million in cash and stock to gain SOFAR's Telelap ALF-X robotic system for minimally invasive surgery.
Valeant is famous for wringing cost savings out of its buyouts, and its tax-advantaged Canadian domicile helps on that front. Now, it's leveraging another address to pare down Salix's tax bill by more than $560 million. But how?